Published in World J Hepatol on March 27, 2015
HepatoDyn: A Dynamic Model of Hepatocyte Metabolism That Integrates 13C Isotopomer Data. PLoS Comput Biol (2016) 0.79
A weighty problem: metabolic perturbations and the obesity-cancer link. Horm Mol Biol Clin Investig (2015) 0.78
Are miRNA-103, miRNA-107 and miRNA-122 Involved in the Prevention of Liver Steatosis Induced by Resveratrol? Nutrients (2017) 0.75
Major components of metabolic syndrome and nutritional intakes in different genotype of UCP2 -866G/A gene polymorphisms in patients with NAFLD. J Transl Med (2016) 0.75
CD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection. World J Hepatol (2016) 0.75
Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol (2017) 0.75
Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol (2017) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA (2005) 9.61
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med (2003) 8.00
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med (2004) 5.49
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr (2003) 2.77
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol (2009) 2.43
Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut (2011) 2.38
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr (2009) 2.24
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (1998) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr (2000) 2.11
Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology (2006) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012) 1.98
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol (2002) 1.70
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol (2011) 1.69
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther (2006) 1.58
Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.55
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2012) 1.52
Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol (2011) 1.48
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol (2013) 1.48
Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol (2003) 1.47
Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol (1991) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology (1990) 1.40
Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis (2007) 1.38
Diet-induced changes in serum transaminase and triglyceride levels in healthy adult men. Role of sucrose and excess calories. Am J Med (1983) 1.36
Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol (1977) 1.31
Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr (1995) 1.30
Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest (2007) 1.23
Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr (2004) 1.23
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol (2008) 1.21
Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol (2007) 1.19
Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol (2008) 1.17
Non-alcoholic steatohepatitis in children and adolescents. Med J Aust (2000) 1.17
Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2001) 1.16
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int (2013) 1.13
Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol (2013) 1.12
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther (2008) 1.11
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One (2014) 1.08
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr (2014) 1.05
Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: the ERA JUMP study. Obesity (Silver Spring) (2009) 1.02
Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr (2013) 1.01
Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol (2012) 0.94
Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients (2014) 0.92
Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2014) 0.92
Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2005) 0.92
Gut microbiota and metabolic syndrome. Intern Emerg Med (2013) 0.91
Prevalence and associated metabolic factors of fatty liver disease in the elderly. Exp Gerontol (2013) 0.91
Physical activity for the prevention and treatment of metabolic disorders. Intern Emerg Med (2013) 0.89
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter. Lab Invest (1991) 0.86
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol (2013) 0.86
Are statins 'IDEAL' for non-alcoholic fatty liver disease? Curr Med Res Opin (2013) 0.84
Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol (2014) 0.83
Oral fructose absorption in obese children with non-alcoholic fatty liver disease. Pediatr Obes (2014) 0.80
Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr (2014) 0.79
Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. Clin Interv Aging (2014) 0.79
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? World J Gastroenterol (2014) 0.78
The impact of weight changes on nonalcoholic Fatty liver disease in adult men with normal weight. Korean J Fam Med (2014) 0.76